Cell Signaling Technology

Product Pathways - MAPK Signaling

p44/42 MAPK (Erk1/2) Control Cell Extracts #9194

Description

p44/42 MAPK (Erk1/2) Negative Control Cell Extracts: Total cell extracts from Jurkat cells treated with U0126 (MEK1/2 Inhibitor) #9903 at 10 μM for 1 hour, to serve as a negative control. Supplied in SDS Sample Buffer.p44/42 MAPK (Erk1/2) Positive Control Cell Extracts: Total cell extracts from Jurkat cells treated with TPA #9905 at 200 nM for 10 minutes, to serve as a positive control. Supplied in SDS Sample Buffer.

Western Blotting

Western Blotting

Western blot analysis of p44/42 MAPK (Erk1/2) Control Cell Extracts, treated with either U0126 or TPA, using Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) Antibody #9101 (left) or p44/42 MAPK (Erk1/2) Antibody #9102 (right).

Western Blotting

Western Blotting

Western blot analysis of p44/42 MAPK (Erk1/2) Control Cell Extracts, using Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb #9106 (green) and p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695 (red).

Applications

Western Blots: As controls, CST recommends using 15 μl of U0126- and TPA-treated p44/42 MAPK (Erk1/2) Cell Extracts. Boil for 3-5 minutes before use.

Background

Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs, such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3), and research investigators consider it an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family, as well as Mos and Tpl2/COT. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors, such as U0126 and PD98059.

  1. Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44.
  2. Baccarini, M. (2005) FEBS Lett 579, 3271-7.
  3. Meloche, S. and Pouysségur, J. (2007) Oncogene 26, 3227-39.
  4. Roberts, P.J. and Der, C.J. (2007) Oncogene 26, 3291-310.
  5. Rubinfeld, H. and Seger, R. (2005) Mol Biotechnol 31, 151-74.
  6. Murphy, L.O. and Blenis, J. (2006) Trends Biochem Sci 31, 268-75.
  7. Dalby, K.N. et al. (1998) J Biol Chem 273, 1496-505.
  8. Marais, R. et al. (1993) Cell 73, 381-93.
  9. Kortenjann, M. et al. (1994) Mol Cell Biol 14, 4815-24.
  10. Owens, D.M. and Keyse, S.M. (2007) Oncogene 26, 3203-13.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products